Liberty Mutual Group Asset Management Inc. cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 20.2% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 9,971 shares of the biotechnology company’s stock after selling 2,518 shares during the period. Liberty Mutual Group Asset Management Inc.’s holdings in United Therapeutics were worth $1,120,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB lifted its position in United Therapeutics by 3.8% during the 4th quarter. Xact Kapitalforvaltning AB now owns 11,474 shares of the biotechnology company’s stock worth $1,698,000 after acquiring an additional 424 shares in the last quarter. American International Group Inc. raised its position in shares of United Therapeutics by 0.6% in the 4th quarter. American International Group Inc. now owns 91,580 shares of the biotechnology company’s stock valued at $13,549,000 after purchasing an additional 524 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in shares of United Therapeutics in the 4th quarter valued at approximately $1,812,000. Mackenzie Financial Corp acquired a new position in shares of United Therapeutics in the 4th quarter valued at approximately $1,690,000. Finally, State of Wisconsin Investment Board raised its position in shares of United Therapeutics by 1.8% in the 4th quarter. State of Wisconsin Investment Board now owns 45,961 shares of the biotechnology company’s stock valued at $6,800,000 after purchasing an additional 802 shares in the last quarter. 99.24% of the stock is currently owned by hedge funds and other institutional investors.
UTHR has been the topic of a number of recent analyst reports. BidaskClub raised United Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 16th. Barclays reaffirmed an “underweight” rating and issued a $105.00 target price (down from $115.00) on shares of United Therapeutics in a research report on Thursday, February 22nd. Credit Suisse Group reaffirmed an “underperform” rating and issued a $115.00 target price (down from $120.00) on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, ValuEngine lowered United Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 27th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $134.00.
Shares of UTHR stock traded up $1.56 on Thursday, hitting $114.17. 282,221 shares of the stock traded hands, compared to its average volume of 404,693. The company has a current ratio of 5.13, a quick ratio of 4.81 and a debt-to-equity ratio of 0.11. The firm has a market cap of $4.90 billion, a P/E ratio of 10.48, a P/E/G ratio of 28.77 and a beta of 1.32. United Therapeutics Co. has a 1-year low of $100.57 and a 1-year high of $152.55.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported $5.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.62 by $1.95. The business had revenue of $389.20 million for the quarter, compared to analyst estimates of $393.96 million. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. The business’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company posted $3.61 EPS. research analysts forecast that United Therapeutics Co. will post 13.04 EPS for the current fiscal year.
In related news, CEO Martine A. Rothblatt sold 301 shares of the company’s stock in a transaction on Tuesday, March 20th. The stock was sold at an average price of $110.48, for a total transaction of $33,254.48. Following the completion of the transaction, the chief executive officer now directly owns 21,652 shares in the company, valued at approximately $2,392,112.96. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Judy D. Olian sold 600 shares of the company’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $112.38, for a total value of $67,428.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 153,134 shares of company stock worth $17,152,504. Corporate insiders own 8.20% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.